No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

The US president has flagged higher-than-expected tariffs of up to 250 per cent on drug imports, which is a potential blow to ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...

Lawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.